Free Trial
NASDAQ:ABVC

ABVC BioPharma Q2 2026 Earnings Results & Report

ABVC BioPharma logo
$0.94 +0.03 (+3.30%)
As of 03:51 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ABVC BioPharma beat analyst earnings expectations in its Q2 2026 results, released August 12, 2026. The company reported EPS of -$0.03 versus the -$0.40 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

ABVC BioPharma EPS Results

Actual EPS
-$0.03
Consensus EPS
-$0.40
Beat/Miss
Beat by +$0.37
One Year Ago EPS
N/A

ABVC BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
$113 thousand
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

ABVC BioPharma Q2 2026 Earnings FAQ

ABVC BioPharma (NASDAQ:ABVC) reported earnings of -$0.03 per share for Q2 2026, beating the consensus estimate of -$0.40. The report was announced on Wednesday, August 12, 2026.

ABVC BioPharma Earnings Headlines

/C O R R E C T I O N - WallachBeth Capital LLC/
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
ABVC BioPharma Delays Quarterly SEC Filing
See More ABVC BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ABVC BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ABVC BioPharma and other key companies, straight to your email.

About ABVC BioPharma

ABVC BioPharma (NASDAQ:ABVC) is a clinical-stage biopharmaceutical company focused on developing botanical drug candidates and medical devices. The company conducts research and development through its subsidiaries and external partners.

Its pipeline includes ABV-1504, a botanical drug candidate being developed for major depressive disorder, and ABV-1505, a candidate for attention-deficit/hyperactivity disorder. These products remain in development and are not described as approved treatments.

Founded in 2015 and headquartered in Fremont, California, ABVC also pursues development opportunities in oncology and other therapeutic areas. Its work includes collaborations and licensing arrangements to advance its product candidates.

View ABVC BioPharma Profile